drugset
drugset / Trial / NCT06860282

A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects

NCT06860282 ↗

Phase 1 Completed 63 enrolled Heronova Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study.

Timeline

Start
2022-12-26
Primary completion
2023-03-27
Completion
2023-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CX2101A Unknown 20 mg Oral
Subject CX2101A Unknown 80 mg Oral
Subject CX2101A Unknown 100 mg Oral
Subject CX2101A Unknown 160 mg Oral
Subject CX2101A Unknown 300 mg Oral
Subject CX2101A Unknown 600 mg Oral
Comparator Remdesivir Small molecule 100 mg Intravenous

Indications

COVID-19 viral pneumonia